Professor JianHui Tian, MD, Shanghai University of Traditional Chinese Medicine, China
Jia Xu, PhD, The University of Alabama at Birmingham, United States of America
Image credit: © wildpixel / Getty Images / iStock
Professor JianHui Tian, MD, Shanghai University of Traditional Chinese Medicine, China
Jia Xu, PhD, The University of Alabama at Birmingham, United States of America
Jia Xu is an assistant Professor in the Department of Genetics and Pathology at the University of Alabama at Birmingham (UAB). Dr. Xu graduated from the University of Texas MD Anderson Cancer Center, USA, and completed postdoctoral training in Dr. Ramon Parsons Lab at the Icahn School of Medicine at Mount Sinai, New York, USA. Dr. Xu has a broad background and track record of publications in cancer research, with specific training and expertise in cancer cell biology and mouse models, cancer signaling, metastasis, drug treatment, and novel therapeutics.
Significant advances have been made in cancer therapy and immunotherapy, including the development of targeted antineoplastic agents, robust tumor cell lines and xenograft models for drug screening, and the exploration of immunological approaches to cancer inhibition. These breakthroughs have provided valuable insights into drug resistance, tumor biology, and the interplay between the immune system and cancer cells. They have also paved the way for innovative immunotherapeutic interventions, such as immune checkpoint inhibitors and CAR T-cell therapy, revolutionizing cancer treatment paradigms.
Future research may focus on unraveling the molecular mechanisms underlying drug resistance, refining xenograft models and antitumor assays, and identifying novel immunotherapeutic targets for enhanced treatment efficacy. Cutting-edge technologies, such as single-cell sequencing and advanced imaging modalities, are poised to provide unprecedented insights into tumor heterogeneity, immune cell dynamics, and the tumor microenvironment, shaping the next generation of cancer therapies.
This Collection seeks to showcase cutting-edge research in cancer therapy and immunotherapy, focusing on the challenges and opportunities in the development of novel treatment strategies, the exploration of immunological approaches, and the understanding of drug resistance mechanisms. We welcome multidisciplinary approaches integrating novel methodologies from medicine, biology, imaging, engineering, bioinformatics, and system analysis.
Developing targeted therapeutic drugs for liver cancer remains a significant scientific and clinical challenge. Previous research by the authors showed that taraxasterol (TS) can enhance the antitumor immune r...
Gastric cancer (GC) is one of the most prevalent malignancies in the world. Most patients are diagnosed at advanced stages of the disease, primarily attributable to the insidious nature of early symptoms and t...
Tumor-associated macrophages (TAMs) are crucial in hepatocellular carcinoma (HCC) development and invasion. This study explores monocyte/ macrophage-associated gene expression profiles in HCC, constructs a pro...
Hepatocellular carcinoma (HCC) is a prevalent malignancy worldwide, characterized by its high malignancy and poor prognosis. Telomeres, crucial components of eukaryotic chromosomes, have been increasingly reco...
Cancer poses significant economic and societal burdens on countries in the coming decades. During chemotherapy, patients frequently encounter adverse reactions. Recent research has revealed that Chinese medici...
T lymphocytes (T cells) are essential components of the adaptive immune system that play a vital role in identifying and eliminating infected and tumor cells. In tumor immunotherapy, T cells have emerged as a ...
The high incidence of recurrence and malignant transformation of colorectal adenoma (CRA) are current issues that need to be addressed in clinical practice. Canmei Formula (CMF) has shown promising results in ...
Chang-Wei-Qing (CWQ) is a widely recognized Traditional Chinese Medicine (TCM) formulation composed of Astragalus, Codonopsis, Atractylodes, Poria, Coix seed, Akebia trifoliata Koidz, Sargentodoxa cuneata, and Vi...
This Collection welcomes submission of original research and review articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal.
Articles for this Collection should be submitted via our submission system, Snapp. Please, select the appropriate Collection title “Cancer Therapy and Immunotherapy: Challenges and Opportunities" under the “Details” tab during the submission stage.
Articles will undergo the journal’s standard peer-review process and are subject to all the journal’s standard policies. Articles will be added to the Collection as they are published.
The Editors have no competing interests with the submissions which they handle through the peer-review process. The peer-review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.